• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Thrombotic Thrombocytopenic Purpura in Oman; Manifestations and Outcome. Retrospective Study
Conclusion:This is the first study that demonstrates the demographic, clinical and survival rate of TTP patients in Oman, and provides a general picture of the TTP patients in our countryDisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Al Hashmi, K. N., Al Dowaiki, S. Tags: 311. Disorders of Platelet Number or Function Source Type: research

Intravascular large B-cell lymphoma presenting as multiple stroke: A case report
Conclusion: IVLBCL is an aggressive disease with high mortality. Timely diagnosis and treatment can be lifesaving.
Source: Medicine - October 1, 2018 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published ...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma
Abstract This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low‐grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28‐day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion ...
Source: British Journal of Haematology - November 28, 2017 Category: Hematology Authors: Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven W. Papish, Jesus G. Berdeja Tags: Research Paper Source Type: research

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
This study is registered with clinicaltrials.gov registry, number NCT00799513. Findings Between March 24, 2009, and Dec 22, 2015, we recruited 48 patients. 46 of 48 enrolled patients were assessable (two patients had unconfirmed diagnoses). 36 (78%) of 46 patients had de novo DLBCL and ten (22%) of 46 patients had transformed DLBCL. At a median follow-up of 25 months (IQR 12–56), 556 lenalidomide courses had been delivered, with an average mean of 12 courses (range 3–41) per patient; 19 patients were still in treatment at a median follow-up of 25 months. Lenalidomide was well tolerated; with the exception of neutropeni...
Source: The Lancet Haematology - February 16, 2017 Category: Hematology Source Type: research

Rare-39. intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the primary cns lymphoma collaborative group (ipcg)
We present a retrospective case series of 72 adults with IVL from 16 cancer centers in 6 countries. IVL was present in the CNS in 55 cases, with a mean age of 61.6 years and more than 90% of patients having neurological deficits at the time of diagnosis. There was a mean diagnostic delay of 20 weeks after presentation of stroke-like symptoms or myelopathy. Eighty-five percent had a poor functional status with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2 with another eight percent diagnosed post-mortem. Serum LDH was elevated in 87% of available patients with no correlation with treatment outco...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Zukas, A., Bennani, N., Chou, C., Johnston, P., ONeill, B. P., Nijland, M., Batchelor, T., Nayak, L., Mrugala, M., Low, J., Omuro, A., Ferreri, A., Nishikawa, R., Mishima, K., Fox, C., Wilson, W., Houillier, C., Chamberlain, M., Schiff, D. Tags: RARE TUMORS Source Type: research

OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
We present a retrospective case series of 65 adults with IVL from 14 cancer centers in 6 countries. IVL was restricted to the CNS in 29 cases, with a mean age of 60 years and 91% of patients having neurological deficits at the time of diagnosis. There was a mean diagnostic delay of 20 weeks after presentation of stroke-like symptoms or myelopathy. Ninety-three percent had a poor functional status with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2. Serum LDH was elevated in 87% of patients with no correlation with treatment outcome. Frontline treatment with intravenous high-dose methotrexate-bas...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Zukas, A. M., Bennani, N., Chou, C., Johnston, P., ONeill, B., Nijland, M., Batchelor, T., Nayak, L., Mrugala, M., Schiff, D. Tags: OS5 Glioma: Clinical Source Type: research

Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction
We report the case of a patient who present a stroke unit with symptoms that were consistent initially with a posterior circulation stroke. Prior chemotherapy with Rituximab, for a lymphoma, had predisposed the patient to infection with the JC virus. Physicians need to be aware of the condition, and patients need to aware of these risks of chemotherapy.
Source: Age and Ageing - June 21, 2016 Category: Geriatrics Authors: Willott, R. H., Sunman, W., Munshi, S. K. Tags: Case Reports Source Type: research

Acute Autonomic Symptoms with Anti-MAG Neuropathy as a Presentation of Small B Cell Lymphoma (P03.023)
CONCLUSIONS: Acute autonomic symptoms can be a rare and a confusing clinical manifestation of anti-MAG distal symmetric polyneuropathy.Thorough work-up including bone marrow biopsy is needed to rule out underlying B cell lymphoma in the presence of a monoclonal gammopathy.Disclosure: Dr. Reyes has nothing to disclose. Dr. Govindarajan has nothing to disclose. Dr. Salgado has received personal compensation in an editorial capacity from Belvoir Media Group as Consulting Editor of A Special Report published by the editors of Heart Advisor Cleveland Clinic STROKE: Advances in Prevention and Treatment of Cerebrovascular Disease.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Reyes, D., Govindarajan, R., Salgado, E. Tags: P03 Dysautonomias Source Type: research

Clinical Spectrum and Course in Individuals with Intravascular Large B-Cell Lymphoma Affecting the Nervous System: A Case Series (P01.102)
CONCLUSIONS: Although IVLBL has distinct pathological features, its clinical presentation can be protean, ranging from mild myopathy to fulminant brain or multi-organ failure. The patient's optimal chance for survival relies on early pathological diagnosis and prompt, aggressive chemotherapy.Disclosure: Dr. Zhong has nothing to disclose. Dr. Oakes has nothing to disclose. Dr. Sonnen has nothing to disclose. Dr. Ransom has nothing to disclose. Dr. Longstreth has nothing to disclose. Dr. Mrugala has received personal compensation for activities with UCB Pharma, Sigma-Tau Pharmaceuticals, and Perceptive Informatics. Dr. Mruga...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Zhong, N., Oakes, P., Sonnen, J., Ransom, B., Longstreth, W. T., Mrugala, M. Tags: P01 Neuro-Oncology: Therapeutics Source Type: research